Skip to main content

Table 4 Effect of PHCSBD on haematological parameters

From: Evaluation of anti-malarial potency of new pyrazole-hydrazine coupled to Schiff base derivatives

Treatment

Dose (mg/kg)

Parasitaemia count

RBC (106/μL)

WBC (103/μL)

PCV (%)

HB (g/dl)

Control

–

5.16 ± 3.88

8.22 ± 1..76

19.50 ± 1.59

5.75 ± 0.96

BePINH

2.5

9.81 ± 1.96

9.77 ± 1.37

38.25 ± 0.83*

10.63 ± 0.19*

10

10.63 ± 1.28*

10.57 ± 2.02

36.50 ± 1.10*

11.03 ± 0.39*

15

10.86 ± 1.11*

10.92 ± 1.70

37.25 ± 0.96*

12.18 ± 0.19*

BePBeH

2.5

8.24 ± 2.92

9.55 ± 1.56

36.87 ± 1.21*

10.71 ± 0.74*

10

9.89 ± 1.31

10.41 ± 1.24

37.02 ± 0.92*

10.87 ± 0.81*

15

10.31 ± 0.29*

10.85 ± 0.82

37.53 ± 1.01*

11.17 ± 1.25*

ACT

5

10.99 ± 1.17*

10.60 ± 1.70

41.50 ± 1.70*

12.00 ± 0.32*

  1. Each value represents the mean ± S.E.M, n = 5
  2. ACT Artemisinin-based Combination Therapy, RBC red blood cells, WBC white blood cells, PCV packed cell volume, HB haemoglobin
  3. *p < 0.05 compared with control (One-way ANOVA; Dunnett’s post hoc)
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us